Portfolio Notes: Track, journal, and analyze every trade

Rani Therapeutics, LLC

Contributing Author

Recent Articles by Rani Therapeutics, LLC

Mar-19	Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results RANI GlobeNewswire
Jan-28	Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer RANI GlobeNewswire
Jan-08	Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen RANI GlobeNewswire
Nov-24	Rani Therapeutics to Participate in the Evercore Healthcare Conference RANI GlobeNewswire
Nov-06	Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update RANI -11.01% RANI -9.20% GlobeNewswire
Oct-30	Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill Capsule at ObesityWeek 2025 RANI -12.65% GlobeNewswire
Oct-23	Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors RANI -13.46% RANI -12.92% GlobeNewswire
Oct-23	Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules RANI -13.46% RANI -12.92% GlobeNewswire
Oct-17	Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules RANI +248.27% GlobeNewswire
Oct-17	Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing RANI +248.27% GlobeNewswire
Aug-07	Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update RANI GlobeNewswire
Jul-15	Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering RANI -38.92% GlobeNewswire
Jul-14	Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery RANI +8.45% GlobeNewswire
May-19	Rani Therapeutics Announces Research Agreement with Chugai RANI +9.27% GlobeNewswire
May-13	Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update RANI -21.42% RANI +15.59% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)